Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Cancer Researchers Call for Academia-Industry Collaboration via Japan NIH
Renowned Japanese cancer researchers and a government official called for academia-industry cooperation through a Japanese version of the US National Institutes of Health (NIH) on December 6. “We need companies to have interests (in academic research) at an early stage”…
To read the full story
Related Article
- 22 Seeds Supported by Drug Discovery Support Network So Far: Dr Kurebayashi of NIBIO
December 9, 2014
Related LEXICON
-
Japan-Version NIH Initiative日本版NIH構想June 30, 2014
ACADEMIA
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…